Tyra Biosciences, Inc.
tyra.bioWhat Do They Do?
Develops oral small-molecule drug candidates for urothelial cancers, skeletal dysplasia and other genetically defined conditions, using its SNÅP platform to design medicines that target FGFR biology.
10-K for FY2025, filed Mar 2, 2026We are a clinical-stage biotechnology company focused on developing next-generation precision medicines for large opportunities in targeted…View ↗
Our in-house precision medicine platform, SNÅP, enables rapid and precise drug design through iterative molecular SNÅPshots that help us…View ↗
We are currently advancing oral dabogratinib in three Phase 2 trials for three outsized market indications: SURF303, evaluating the…View ↗
How Are They Changing?
- Net income
-
Sources
10-Q for Q2 FY2026, filed Aug 4, 2026
−$45.6MView ↗
- ▲ +62% (Loss)
- vs −$28.1M in Q2 FY2025
Who Do They Compete With?
Competes with Urogen, Steba Biotech, Ferring, Sustained Therapeutics, Janssen Pharmaceutical, CG Oncology, BioMarin, Ascendis, BridgeBio, Bayer, Exelixis, Eli Lilly, BMS, CStone Pharmaceuticals, Blueprint Medicine, Everest Medicine, Abbisko Therapeutics, Incyte, Taiho Oncology, and Elevar
10-K for FY2025, filed Mar 2, 2026For oral dabogratinib in LG-UTUC, the only agent commercially available is Urogen’s Jelmyto, a hydrogel reformulation of mitomycin C, which…View ↗
Loading...
